Heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Reconstitution is required before use in most assays |
| Solubility class | Freely soluble in water and acetonitrile; sparingly soluble in nonpolar solvents | Aqueous solutions may benefit from slight acidification |
| Typical storage temperature | -20 °C or lower, desiccated and protected from light | Short-term transport at 2-8 °C is common practice |
| Primary degradation routes | Oxidation, hydrolysis, aggregation | Tryptophan and histidine residues are the main oxidation targets |
| Quality marker | Chromatographic purity by peak area | Does not capture counter-ion content or residual solvents |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Nuclear fuel data and analysis from the U.S. Energy Information Administration World Uranium deposit maps Dittmar, William (1888). "Uranium" . Encyclopædia Britannica. Vol. XXIV (9th ed.). p. 7. Annotated bibliography for uranium from the Alsos Digital Library NLM Hazardous Substances Databank – Uranium, Radioactive CDC – NIOSH Pocket Guide to Chemical Hazards ATSDR Case Studies in Environmental Medicine: Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services Uranium at The Periodic Table of Videos (University of Nottingham)
Hormones in cattle had been studied in North America for 50 years prior to the ban, accompanied by long-term use in over 20 countries. Canada and the United States asserted that these practices provided empirical evidence of long-term safety. The EU had already established other measures that restricted the import of North American beef. The primary North American product affected by the new ban was edible offal. A series of "hormone scandals" emerged in Italy in the late 1970s and early 1980s. The first, in 1977, was the discovery of premature puberty in northern Italian schoolchildren. Investigators cast suspicion on school lunches that used illegal hormone-treated meat. No concrete evidence was found–no samples of the suspect meals were available for analysis. In 1980 diethylstilbestrol (DES), another illegal synthetic hormone, was discovered in veal-based baby foods. Little or no scientific evidence supported these restrictions. However, consumer groups successfully influenced the European Parliament to enact regulations in the 1980s, and influenced public perceptions. In the US at the time, consumer organizations evinced little interest prior to the 1980s, and regulations were driven by a coalition of export-oriented industry and farming interests, opposed only by organic farming groups. Until 1980, the use of growth hormones was completely prohibited in Italy, Denmark, the Netherlands, and Greece. Germany, the EU's largest beef producer at the time, prohibited only exogenous growth hormones.
For Psylocke’s new look, which I collaborated on with Chris Claremont, she appears on the cover in armor. That was my first take on the character, which I had to get done for the cover before I had finished the interior look, and I don’t think Chris had signed off on yet. He didn’t like that direction as much -- he wanted something slinkier, more like Elektra -- that you eventually see inside that issue. But that discussion led us to modify the story a little. When you first see her, she’s in that armor, and through a psychic conflict, you see it smashed off of her body to unveil the new costume that Chris wanted. A 1993 story by Fabian Nicieza would retroactively establish that Braddock's changed appearance was the product of a body swap between Braddock and the assassin Kwannon. In the Claremont-written X-Treme X-Men #2 (2001), the character dies, her comic book death lasting until 2005's Uncanny X-Men #455. During the 2018 "Hunt for Wolverine" storyline, the psychic vampire Sapphire Styx absorbs Braddock's soul, leaving her body dead. After destroying Styx from the inside with assistance from a fragment of Wolverine's soul, Braddock reconstitutes her original body with Styx's remaining soul power. During the Dawn of X, Braddock subsequently took up her brother Brian's former title of Captain Britain, forming a new iteration of Excalibur with Apocalypse, Gambit, Rogue, Jubilee, and Rictor, to protect the Kingdom of Avalon.
Sources: en.wikipedia.org
During Alice in Chains' hiatus, reports of Staley's addiction began to gain widespread circulation in fan and media communities, in part due to changes in his physical condition brought on by prolonged heroin abuse. Alice in Chains regrouped to record Alice in Chains, sometimes referred to as "Tripod" due to the cover featuring a three-legged dog, which was released in November 1995. The album debuted at the top of the U.S. charts, and has since been awarded—along with Facelift and Jar of Flies—double platinum status. With the exceptions of "Grind", "Heaven Beside You", and "Over Now", the lyrics were all written by Staley, making this album his greatest lyrical contribution to the band's catalog. To accompany the album, the band released a home video, The Nona Tapes, but the band lapsed again, failing to complete tours planned in support of the album. When asked about the frustration of not touring to support the record, Cantrell provided some insight into how Staley's addictions led to tensions within the band: "Very frustrating, but we stuck it out. We rode the good times together, and we stuck together through the hard times. We never stabbed each other in the back and spilled our guts and [did] that kind of bullshit that you see happen a lot." "Drugs worked for me for years", Staley told Rolling Stone in February 1996, "and now they're turning against me, now I'm walking through hell and this sucks. I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high.
== Early life == Brian Rafat Awadis was born on November 19, 1996 in San Diego, California, to immigrant Chaldo-Assyrian parents from Tel Keppe, Iraq. His father owns two stores. He graduated from Mira Mesa Senior High School and attended San Diego Miramar College before dropping out during his freshman year to pursue his YouTube career full-time. He can speak the Suret language, although not fluently.
During Bryson's 20-month tenure as Lilly's president and CEO, the company reported its first quarterly loss as a publicly traded company. In 1993, Randall L. Tobias, vice chairman of AT&T Corporation and a Lilly board member, was named Lilly's chairman, president, and CEO, the first president and CEO recruited from outside of the company. In 1994, Lilly separated its medical device division. It also acquired PCS Systems, the largest drug benefits health maintenance organization at the time, for $4 billion. Released in 1996, Zyprexa (Olanzapine) (for schizophrenia and bipolar disorder, as well as off-label uses) (see Illegal marketing of Zyprexa) was the company's best-selling drug through 2010, when the patent expired. In May 1996, the Food and Drug Administration approved gemcitabine (Gemzar) for the treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiation therapy. Gemzar is also routinely used to treat non-small cell lung cancer. In 1998, the company dedicated new laboratories for clinical research at the Indiana University Medical Center in Indianapolis. Sidney Taurel, former chief operating officer of Lilly, was named CEO in July 1998 to replace Tobias, who retired. Taurel became chairman of the board in January 1999. Taurel retired as CEO in March 2008, but remained as chairman of the board until 31 December 2008. John C. Lechleiter was elected as Lilly's CEO and president, effective 1 April 2008.
Epidermal growth factor (EGF) is a protein that stimulates cell growth and differentiation by binding to its receptor, EGFR. Human EGF is 6-kDa and has 53 amino acid residues and three intramolecular disulfide bonds. EGF was originally described as a secreted peptide found in the submaxillary glands of mice and in human urine. EGF has since been found in many human tissues, including platelets, submandibular gland (submaxillary gland), and parotid gland. Initially, human EGF was known as urogastrone.
Sources: en.wikipedia.org
sovramagnificentissimamente (cited by Dante Alighieri in De vulgari eloquentia), 27 letters, "in a way that is more than magnificent by far" (archaic); incontrovertibilissimamente, 27 letters, "in a way that is very difficult to falsify"; particolareggiatissimamente, 27 letters, "in an extremely detailed way"; anticostituzionalissimamente, 28 letters, "in a way that strongly violates the constitution". The longest accepted neologism is psiconeuroendocrinoimmunologia (30 letters).. Other long words are:
Locomotive. Vossloh Locomotives (owned by Chinese CRRC) manufactures three models of diesel-hydraulic (G6, G12, G18) and two models of diesel-electric (DE12, DE18) locomotives. Other manufacturer was Voith Turbo Lokomotivtechnik, but closed in 2014 year. Both firms are in Kiel.
=== West Malaysia === Ben's Independent Grocer Big 10 Grocer Billion Supermarket BS Fresh Mart Ceria 99 Checkers Hypermarket CLC Pasaraya C-Mart Eco-Shop Family Foods Market Family Market Family Store Fresh Choice Supermarket GAMA Supermarket & Departmental Store GCH Retail Cold Storage Giant Hypermarket Mercató GT Mart Haniffa Department Store HeroMarket Homes Fresh Grocer Isetan Foodmarket (by Isetan) Jaya Grocer K Grocer LuLu Hypermarket (Closed) MeMiZoooZooo Grocer Nirwana Hypermarket NSK Grocer (supermarket chain of NSK Trade City) OMG Wholesale Mart Pacific Grocer Pak Grocer Pantai Selamat Supermarket Pasaraya Aneka Pasaraya Borong Big Pasaraya Borong Matahari Pasaraya CS Pasaraya Gold Star Best Mart Pasaraya Grand Union Pasaraya K Ceria Pasaraya Megamart Pasaraya Rakan Qra Redtick (serving East Malaysia) Sabasun HyperRuncit Salamku Supermarket Sam's Groceria Segi Fresh Selections Groceries SOGO Star Grocer ST Rosyam Mart Sunshine Super Cowboy Super Seven TMC Supermarket TF Value Mart The Food Merchant TMG Mart The Store Urban Marketplace Village Grocer
==== Infections: HIV-AIDS, measles, RSV, others ==== The role of SP in HIV-AIDS has been well-documented. Doses of aprepitant greater than those tested to date are required for demonstration of full efficacy. Respiratory syncytial and related viruses appear to upregulate SP receptors, and rat studies suggest that NK1RAs may be useful in treating or limiting long term sequelae from such infections. Entamoeba histolytica is a unicellular parasitic protozoan that infects the lower gastrointestinal tract of humans. The symptoms of infection are diarrhea, constipation, and abdominal pain. This protozoan was found to secrete serotonin as well as Substance P and neurotensin.
=== Psychological motivations === Psychology is another factor to take into consideration in doping in sport. It becomes a behavioral issue when the athlete acknowledges the health risks associated with doping, yet participates in it anyway. This has to do with the psychological thinking that the drug will make one feel invincible. The individuals are very egotistic in their way of thinking and their motivation is dependent on the performance enhancement drug since they believe that it delivers the results. On a study on health psychology, Quirk points out three different psychological aspects that lead one to dope: social cognition, stress and strain, and addiction. The social and physical pressures can alter an athlete's way of thinking, leading them to believe that they must take performance enhancement drugs since everyone else is doing it, known as "the doping dilemma." This also causes athletes to be hesitant to consult with a doctor about their steroid use, putting themselves at more risk with health problems.
Sources: en.wikipedia.org
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.
Reversed-phase chromatography establishes a purity profile, while electrospray or matrix-assisted laser desorption mass spectrometry confirms that the observed mass matches the expected sequence. Together they support, but do not fully prove, identity and purity.
Reviews generally characterise it as thin, dominated by small and often uncontrolled studies. Several authors explicitly note that findings on pigmentation, appetite and sexual function have not been confirmed in adequately powered controlled trials.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.